Signaturefd LLC Acquires 598 Shares of Eli Lilly and Company (NYSE:LLY)

Signaturefd LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 2.6% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 23,973 shares of the company’s stock after acquiring an additional 598 shares during the period. Signaturefd LLC’s holdings in Eli Lilly and Company were worth $13,975,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of LLY. Norges Bank bought a new position in shares of Eli Lilly and Company during the fourth quarter valued at $3,416,206,000. International Assets Investment Management LLC raised its stake in Eli Lilly and Company by 61,268.8% during the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after buying an additional 7,330,815 shares during the last quarter. Moneta Group Investment Advisors LLC raised its stake in Eli Lilly and Company by 102,752.2% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock worth $1,992,374,000 after buying an additional 5,440,731 shares during the last quarter. Morgan Stanley raised its stake in Eli Lilly and Company by 44.1% during the fourth quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock worth $4,411,740,000 after buying an additional 3,691,436 shares during the last quarter. Finally, Imprint Wealth LLC raised its stake in Eli Lilly and Company by 53,716.8% during the second quarter. Imprint Wealth LLC now owns 1,751,200 shares of the company’s stock worth $175,120,000 after buying an additional 1,747,946 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 54,032 shares of Eli Lilly and Company stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $645.07, for a total value of $34,854,422.24. Following the sale, the insider now owns 99,488,598 shares of the company’s stock, valued at $64,177,109,911.86. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Down 2.6 %

Shares of NYSE LLY traded down $19.64 during mid-day trading on Friday, reaching $726.31. 3,505,526 shares of the company’s stock traded hands, compared to its average volume of 2,202,924. The stock has a market cap of $690.11 billion, a P/E ratio of 125.23, a PEG ratio of 1.63 and a beta of 0.34. The business has a 50-day simple moving average of $763.96 and a 200 day simple moving average of $659.59. Eli Lilly and Company has a 1-year low of $369.76 and a 1-year high of $800.78. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company had revenue of $9.35 billion for the quarter, compared to analyst estimates of $8.95 billion. During the same period last year, the firm earned $2.09 earnings per share. The firm’s revenue was up 28.1% on a year-over-year basis. On average, analysts expect that Eli Lilly and Company will post 12.52 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on LLY shares. The Goldman Sachs Group lifted their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. Citigroup lifted their target price on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the stock a “buy” rating in a research note on Tuesday, April 2nd. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Barclays raised their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. Finally, Morgan Stanley raised their price target on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a report on Friday, February 16th. Three equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company presently has an average rating of “Moderate Buy” and a consensus price target of $728.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.